{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T08:18:01Z","timestamp":1770711481465,"version":"3.49.0"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T00:00:00Z","timestamp":1702857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Different medication prescription patterns have been associated with varying course of disease and outcomes in COVID-19. Health claims data is a rich source of information on disease treatment and outcomes. We aimed to investigate drug prescription patterns and their association with mortality and hospitalization via insurance data for a relatively long period of the pandemic in Iran.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrieved hospitalized patients\u2019 data from Iran Health Insurance Organization (IHIO) spanning 26\u2009months (2020\u20132022) nationwide. Included were patients with ICD-10 codes U07.1\/U07.2 for confirmed\/suspected COVID-19. A case was defined as a single hospitalization event for an individual patient. Multiple hospitalizations of a patient within a 30-day interval were aggregated into a single case, while hospitalizations with intervals exceeding 30\u2009days were treated as independent cases. The Anatomical Therapeutic Chemical (ATC) was used for medications classification. The two main study outcomes were general and intensive care unit (ICU) hospitalization periods and mortality. Besides, various demographic and clinical associate factors were analyzed to derive the associations with medication prescription patterns and study outcomes using accelerated failure time (AFT) and logistic regression models.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>During the 26\u2009months of the study period, 1,113,678 admissions with COVID-19 diagnosis at hospitals working in company with IHIO were recorded. 917,198 cases were detected from the database, among which 51.91% were females and 48.09% were males. Among the main groups of medications, antithrombotics (55.84% [95% CI: 55.74\u201355.94]), corticosteroids (54.14% [54.04\u201354.24]), and antibiotics (42.22% [42.12\u201342.32]) were the top used medications among cases with COVID-19. Investigation of the duration of hospitalization based on main medication groups showed antithrombotics (adjusted median ratio\u2009=\u20090.94 [0.94\u20130.95]) were significantly associated with shorter periods of overall hospitalization. Also, antithrombotics (adjusted odds ratio\u2009=\u20090.74 [95%CI, 0.73\u20130.76]), corticosteroids (0.97 [0.95\u20130.99]), antivirals (0.82 [0.80\u20130.83]), and ACE inhibitor\/ARB (0.79 [0.77\u20130.80]) were significantly associated with lower mortality.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Over 2\u2009years of investigation, antithrombotics, corticosteroids, and antibiotics were the top medications for hospitalized patients with COVID-19. Trends in medication prescription varied based on various factors across the country. Medication prescriptions could potentially significantly impact the trends of mortality and hospitalization during epidemics, thereby affecting both health and economic burdens.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2023.1280434","type":"journal-article","created":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T09:42:21Z","timestamp":1702892541000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Drug prescription patterns and their association with mortality and hospitalization duration in COVID-19 patients: insights from big data"],"prefix":"10.3389","volume":"11","author":[{"given":"Reza","family":"Mehrizi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Golestani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad-Reza","family":"Malekpour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossein","family":"Karami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Mahdi","family":"Nasehi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Effatpanah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossein","family":"Ranjbaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Shahali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali Akbari","family":"Sari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajabali","family":"Daroudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,12,18]]},"reference":[{"key":"ref1","volume-title":"Covid-19: WHO declares end of global health emergency","author":"Wise","year":"2023"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.vacun.2023.05.002","article-title":"The end of COVID-19 public health emergency of international concern (PHEIC): and now what?","volume":"24","author":"Torner","year":"2023","journal-title":"Vacunas"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/S0140-6736(21)02751-3","article-title":"Health system performance in Iran: a systematic analysis for the global burden of disease study 2019","volume":"399","year":"2022","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.34172\/ijhpm.2020.252","article-title":"A report on statistics of an online self-screening platform for COVID-19 and its effectiveness in Iran","volume":"11","author":"Azadnajafabad","year":"2021","journal-title":"Int J Health Policy Manag"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"445","DOI":"10.34172\/aim.2021.63","article-title":"Non-communicable Diseases' contribution to the COVID-19 mortality: a global warning on the emerging Syndemics","volume":"24","author":"Azadnajafabad","year":"2021","journal-title":"Arch Iran Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1007\/s40200-021-00877-1","article-title":"Dissection of non-pharmaceutical interventions implemented by Iran, South Korea, and Turkey in the fight against COVID-19 pandemic","volume":"20","author":"Keykhaei","year":"2021","journal-title":"J Diabetes Metab Disord"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1017\/dmp.2022.141","article-title":"Consecutive waves of COVID-19 in Iran: various dimensions and probable causes","volume":"17","author":"Heidari","year":"2022","journal-title":"Disaster Med Public Health Prep"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"10747","DOI":"10.1038\/s41598-023-37912-5","article-title":"Exploring the clinical benefit of ventilation therapy across various patient groups with COVID-19 using real-world data","volume":"13","author":"Abbasi-Kangevari","year":"2023","journal-title":"Sci Rep"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1017\/S0266462300000787","article-title":"Use of insurance claims data in measuring quality of care","volume":"6","author":"Lohr","year":"1990","journal-title":"Int J Technol Assess Health Care"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s10742-020-00232-6","article-title":"Chronic diseases and multimorbidity in Iran: a study protocol for the use of Iranian health insurance organization\u2019s claims database to understand epidemiology, health service utilization, and patient costs","volume":"21","author":"Ebrahimoghli","year":"2021","journal-title":"Health Services Outcomes Res Methodol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/jrpp.jrpp_6_22","article-title":"Evaluation of COVID-19 treatments in Iran in comparison with local therapeutic recommendations: a population-level study on utilization and costs of prescription drugs","volume":"11","author":"Hashemi-Meshkini","year":"2022","journal-title":"J Res Pharmacy Pract"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/j.sapharm.2023.08.011","article-title":"Poor regulation, desperation, and misinformation, a countrywide analysis of self-medication and prescription patterns in Ecuador during the COVID-19 pandemic","volume":"19","author":"Ortiz-Prado","year":"2023","journal-title":"Res Soc Adm Pharm"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"5844","DOI":"10.3390\/ijerph17165844","article-title":"Analysis of risk factors on readmission cases of COVID-19 in the Republic of Korea: using Nationwide health claims data","volume":"17","author":"Jeon","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1061307","DOI":"10.3389\/fpubh.2023.1061307","article-title":"Effect of the chronic medication use on outcome measures of hospitalized COVID-19 patients: evidence from big data","volume":"11","author":"Malekpour","year":"2023","journal-title":"Front Public Health"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e050051","DOI":"10.1136\/bmjopen-2021-050051","article-title":"Association of the patterns of use of medications with mortality of COVID-19 infection: a hospital-based observational study","volume":"11","author":"Wallace","year":"2021","journal-title":"BMJ Open"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"100101","DOI":"10.1016\/j.rcsop.2021.100101","article-title":"Pattern of medication utilization in hospitalized patients with COVID-19 in three District Headquarters hospitals in the Punjab province of Pakistan","volume":"5","author":"Mustafa","year":"2022","journal-title":"Explor Res Clin Soc Pharm"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3390\/antibiotics11030333","article-title":"Prescription patterns of drugs given to hospitalized COVID-19 patients: a cross-sectional study in Colombia","volume":"11","author":"Valladales-Restrepo","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"ref18","first-page":"1","article-title":"The Iranian health insurance system; past experiences, present challenges and future strategies","volume":"41","author":"Davari","year":"2012","journal-title":"Iran J Public Health"},{"key":"ref19","year":""},{"key":"ref20","year":"2019"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1186\/s12889-022-13649-0","article-title":"National geographical pattern of COVID-19 hospitalization, case fatalities, and associated factors in patients covered by Iran health insurance organization","volume":"22","author":"Damiri","year":"2022","journal-title":"BMC Public Health"},{"key":"ref22","year":"2023"},{"key":"ref23","volume-title":"Food and Drug Administration (FDA) 0f Iran - drugs list","year":"2023"},{"key":"ref24","year":"2023"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.7326\/M21-0857","article-title":"Use of hydroxychloroquine, remdesivir, and dexamethasone among adults hospitalized with COVID-19 in the United States: a retrospective cohort study","volume":"174","author":"Mehta","year":"2021","journal-title":"Ann Intern Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"5367","DOI":"10.1002\/jmv.27049","article-title":"Treatment patterns in US patients hospitalized with COVID-19 and pulmonary involvement","volume":"93","author":"Best","year":"2021","journal-title":"J Med Virol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s40264-020-00976-7","article-title":"Azithromycin in COVID-19 patients: pharmacological mechanism, clinical evidence and prescribing guidelines","volume":"43","author":"Sultana","year":"2020","journal-title":"Drug Saf"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"e000806","DOI":"10.1136\/bmjresp-2020-000806","article-title":"Rationale for azithromycin in COVID-19: an overview of existing evidence. BMJ open","volume":"8","author":"Gyselinck","year":"2021","journal-title":"Respir Res"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.amjcard.2020.08.005","article-title":"The effect of anticoagulation use on mortality in COVID-19 infection","volume":"134","author":"Salah","year":"2020","journal-title":"Am J Cardiol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1055\/a-1347-6070","article-title":"Heparin in COVID-19 patients is associated with reduced in-hospital mortality: the multicenter Italian CORIST study","volume":"121","author":"Di Castelnuovo","year":"2021","journal-title":"Thromb Haemost"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1076029620960797","DOI":"10.1177\/1076029620960797","article-title":"The use of therapeutic-dose anticoagulation and its effect on mortality in patients with COVID-19: a systematic review","volume":"26","author":"Wijaya","year":"2020","journal-title":"Clin Appl Thromb Hemost"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e192","DOI":"10.1111\/bjh.16968","article-title":"COVID-19 mortality in patients on anticoagulants and antiplatelet agents","volume":"190","author":"Sivaloganathan","year":"2020","journal-title":"Br J Haematol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1007\/s11239-022-02681-x","article-title":"Efficacy and safety of heparin full-dose anticoagulation in hospitalized non-critically ill COVID-19 patients: a meta-analysis of multicenter randomized controlled trials","volume":"54","author":"Pilia","year":"2022","journal-title":"J Thromb Thrombolysis"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s00408-023-00599-6","article-title":"The effect of heparin full-dose anticoagulation on survival of hospitalized, non-critically ill COVID-19 patients: a meta-analysis of high quality studies","volume":"201","author":"Pilia","year":"2023","journal-title":"Lung"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/ijlh.13500","article-title":"COVID-19: thrombosis, thromboinflammation, and anticoagulation considerations","author":"Levy","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3390\/jpm12060877","article-title":"Antibiotic prescription and in-hospital mortality in COVID-19: a prospective multicentre cohort study","volume":"12","author":"Pinte","year":"2022","journal-title":"J Pers Med"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"107157","DOI":"10.1016\/j.intimp.2020.107157","article-title":"Clinical characteristics and antibiotics treatment in suspected bacterial infection patients with COVID-19","volume":"90","author":"Liu","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.cmi.2020.09.041","article-title":"Recommendations for antibacterial therapy in adults with COVID-19 - an evidence based guideline","volume":"27","author":"Sieswerda","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"106324","DOI":"10.1016\/j.ijantimicag.2021.106324","article-title":"Increased antimicrobial resistance during the COVID-19 pandemic","volume":"57","author":"Lai","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.jiph.2021.02.011","article-title":"Antimicrobial resistance threats in the emerging COVID-19 pandemic: where do we stand?","volume":"14","author":"Ghosh","year":"2021","journal-title":"J Infect Public Health"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","year":"2021","journal-title":"N Engl J Med"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.medcli.2022.03.013","article-title":"Effectiveness of corticosteroids to treat coronavirus disease 2019 symptoms: a meta-analysis","volume":"159","author":"Zeng","year":"2022","journal-title":"Med Clin"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1177\/0897190021998502","article-title":"A review of the evidence for corticosteroids in COVID-19","volume":"35","author":"Johns","year":"2022","journal-title":"J Pharm Pract"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"103492","DOI":"10.1016\/j.resp.2020.103492","article-title":"Pros and cons of corticosteroid therapy for COVID-19 patients","volume":"280","author":"Mattos-Silva","year":"2020","journal-title":"Respir Physiol Neurobiol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"606429","DOI":"10.3389\/fmed.2020.606429","article-title":"Mortality benefit of Remdesivir in COVID-19: a systematic review and meta-analysis","volume":"7","author":"Bansal","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1016\/S0140-6736(22)00519-0","article-title":"Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO solidarity randomised trial and updated meta-analyses","volume":"399","year":"2022","journal-title":"Lancet"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"Cd014962","DOI":"10.1002\/14651858.CD014962.pub2","article-title":"Remdesivir for the treatment of COVID-19","volume":"1","author":"Grundeis","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1159\/000512592","article-title":"Association of sex, age, and comorbidities with mortality in COVID-19 patients: a systematic review and meta-analysis","volume":"64","author":"Biswas","year":"2021","journal-title":"Intervirology"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"704666","DOI":"10.3389\/fmed.2021.809134","article-title":"Metformin in patients with COVID-19: a systematic review and meta-analysis","volume":"8","author":"Li","year":"2021","journal-title":"Front Med"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1136\/thoraxjnl-2020-215322","article-title":"Renin-angiotensin system blocker and outcomes of COVID-19: a systematic review and meta-analysis","volume":"76","author":"Lee","year":"2021","journal-title":"Thorax"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S2213-2600(20)30116-8","article-title":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?","volume":"8","author":"Fang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1080\/10641963.2022.2071914","article-title":"Association between hypertension and prognosis of patients with COVID-19: a systematic review and meta-analysis","volume":"44","author":"Qian","year":"2022","journal-title":"Clin Exp Hypertens"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1080\/22221751.2020.1746200","article-title":"Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension","volume":"9","author":"Meng","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.3390\/cells9071652","article-title":"COVID-19, renin-angiotensin system and endothelial dysfunction","volume":"9","author":"Amraei","year":"2020","journal-title":"Cells"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2023.1280434\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T09:42:27Z","timestamp":1702892547000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2023.1280434\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,18]]},"references-count":55,"alternative-id":["10.3389\/fpubh.2023.1280434"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2023.1280434","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,18]]},"article-number":"1280434"}}